

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 26D0440645	(X3) Date Survey Completed 12/15/2022
Name of Provider or Supplier Arthritis Consultants, Inc	Street Address, City, State 522 N New Ballas, Suite 240, Saint Louis, MO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of 2022 hematology proficiency testing (PT) results reported to the CLIA database by the PT provider and phone interview with the technical consultant, the laboratory failed to successfully participate in PT. See D-tag 2130; unsuccessful performance in two out of three consecutive white blood cell and hemoglobin PT challenges. See D-tag 2131; unsuccessful performance in two out of three consecutive hematology specialty testing events.</p>
D2130	<p>HEMATOLOGY CFR(s): 493.851(f)</p>

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of hematology proficiency testing (PT) records for 2022 and phone interview with the technical consultant, the laboratory failed to achieve satisfactory performance for white blood cell and hemoglobin analytes in two out of three consecutive PT events. Findings: 1. Review of hematology PT results for the first event of 2022 revealed the laboratory obtained an unacceptable score of 40 percent for white blood cell analyte and unacceptable score of 0 percent for the hemoglobin analyte. 2. Review of hematology PT results for the third event of 2022 revealed the laboratory obtained an unacceptable score of 60 percent for the white blood cell analyte and unacceptable score of 60 percent for the hemoglobin analyte 3. Phone interview with the technical consultant on December 15, 2022 at 1:30 PM confirmed the laboratory failed to achieve satisfactory performance for white blood cell and hemoglobin analytes in two out of three consecutive PT events.

D2131

HEMATOLOGY

CFR(s): 493.851(g)

Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of hematology proficiency testing (PT) records for 2022 and phone interview with the technical consultant, the laboratory failed to achieve an overall testing event score of satisfactory performance for the specialty of hematology in two out of three consecutive PT events. Findings: 1. Review of hematology PT results for the first event of 2022 revealed the laboratory obtained an unacceptable score of 56 percent for the specialty of hematology. 2. Review of hematology PT results for the third event of 2022 revealed the laboratory obtained an unacceptable score of 63 percent for the specialty of hematology. 3. Phone interview with the technical consultant on December 15, 2022 at 1:30 PM confirmed the laboratory failed to achieve satisfactory performance for specialty of hematology in two out of three consecutive PT events.